Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cochran Collaboration ESA Meta-Analysis Underscores Survival Risk

Executive Summary

A meta-analysis of patient level data from over 10,000 clinical trial patients suggests that use of erythropoiesis-stimulating agents may have an adverse survival impact in the still-approved uses in supportive care for oncology

You may also be interested in...



Amidst ESA Upheaval, FDA Used Mircera Review To Outline Trial “Wish List”

FDA's review of Roche's Mircera BLA became a forum for the agency to set forth a "wish list" for future development of erythropoietin stimulating agents that reflected the seismic upheavals in the conventional understanding of the safety of erythropoietin products

Amidst ESA Upheaval, FDA Used Mircera Review To Outline Trial “Wish List”

FDA's review of Roche's Mircera BLA became a forum for the agency to set forth a "wish list" for future development of erythropoietin stimulating agents that reflected the seismic upheavals in the conventional understanding of the safety of erythropoietin products

As Amgen Drops Some ESA “Overhangs,” New Payment Threat Appears

Amgen could be facing a new threat on the reimbursement front just days after celebrating the removal of several "major overhangs" to its erythropoiesis-stimulating agents during its second quarter earnings call

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel